Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD Meeting Abstract
| Authors: | Le, X.; Hendriks, L.; Morabito, A.; Bonanno, L.; Okamoto, I.; Goldman, J. W.; Yu, H. A.; Brustugun, O. T.; Halvorsen, T. O.; Kim, Y. J.; Marrone, K.; Cho, B. C.; Riess, J. W.; De Langen, A. J.; Piotrowska, Z.; Ambrose, H.; Smith, P.; Lehman, J. M.; Fraenkel, P. G.; Goldberg, S. B. |
| Abstract Title: | Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD |
| Meeting Title: | European Lung Cancer Congress (ELCC) 2025 |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 20 |
| Issue: | 3 Suppl. 1 |
| Meeting Dates: | 2025 Mar 26-29 |
| Meeting Location: | Paris, France |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2025-03-01 |
| Start Page: | S2 |
| End Page: | S4 |
| Language: | English |
| ACCESSION: | WOS:001469780300004 |
| PROVIDER: | wos |
| DOI: | 10.1016/s1556-0864(25)00196-0 |
| Notes: | Meeting Abstract: 10 -- Source: Wos |
